EquityBulls

2022-05-20 17:39:20

Home
Commodities
Industry News
IPO
Mutual Funds
Others
Research
Watch List

Latest News

Southern Magnesium and Chemicals Ltd Q4FY22 loss at Rs. 21.03 lakhs
Archidply Industries Q4FY22 PAT climbs to Rs. 2.90 crore
Bajaj Hindusthan Sugar Ltd Q4 FY22 consolidated PAT at Rs. 59.72 crores
Ador Multiproducts Ltd Q4FY22 consolidated loss at Rs. 2.65 crore
Goldiam International Ltd recommends final dividend of Rs. 0.60

Keywords Selected: INE326A01037

Stock Report

Lupin Ltd recommends dividend of Rs. 4
Lupin receives approval from U.S. FDA for Iloperidone Tablets
Lupin receives approval from U.S. FDA for Pregabalin Capsules
Lupin Launches its Reference Laboratory in Guwahati, Assam
Lupin appoints Diana Amador-Toro as Senior Vice President, Global Compliance
Lupin and Yabao announce Strategic Partnership in China
Lupin receives Tentative Approval from U.S. FDA for Tenofovir Alafenamide Tablets
Lupin receives approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets 25 mg
Lupin Launches Merzee® Capsules in the United States
Lupin Completes Acquisition of Brands from Anglo-French
U.S. FDA inspection at Lupin's Tarapur manufacturing facility
Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region
Lupin to acquire portfolio of brands from Anglo-French Drugs & Industries Limited
U.S. FDA inspection of the Company's Somerset, New Jersey, USA facility
Lupin receives approval from U.S. FDA for Sildenafil for Oral Suspension
Lupin receives approval from U.S. FDA for Vigabatrin for Oral Solution USP
Lupin Launches its First Reference Laboratory in East India
Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease
Lupin signs on Mary Kom for its Women's Cardiovascular Health Awareness Initiative, Shakti
Lupin receives approval from U.S. FDA for Efinaconazole Topical Solution
Lupin Launches Sevelamer Hydrochloride Tablets in the United States
Lupin announces Executive Leadership change
Lupin announces FDA Approval of Supplemental New Drug Application for SOLOSEC®
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®

Latest Post

Southern Magnesium and Chemicals Ltd Q4FY22 loss at Rs. 21.03 lakhs
Archidply Industries Q4FY22 PAT climbs to Rs. 2.90 crore
Bajaj Hindusthan Sugar Ltd Q4 FY22 consolidated PAT at Rs. 59.72 crores
Ador Multiproducts Ltd Q4FY22 consolidated loss at Rs. 2.65 crore
Goldiam International Ltd recommends final dividend of Rs. 0.60

Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

Home
Contact
Our Team

Contact

The website is developed and maintained by Chennai Scripts

No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2021